[
    {
        "role": "user",
        "content": "what%20is%20the%20non%2024%20medication%20given%20to%20blind%20people%20with%20no%20light%20perception.%20how%20does%20it%20work"
    },
    {
        "role": "assistant",
        "content": "For people who are totally blind and have *no light perception*, the medication approved to treat **non-24-hour sleep-wake disorder** (Non-24) is **tasimelteon**, sold under the brand name *Hetlioz*. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK548636/?utm_source=openai))\n\nHere\u2019s how it works and what\u2019s known about it:\n\n---\n\n### What is Non-24-Hour Sleep-Wake Disorder (Non-24)\n\n- Non-24 is a circadian rhythm sleep disorder where the body's internal clock (the circadian pacemaker, located in a part of the brain called the suprachiasmatic nucleus, or SCN) does not synchronize to the 24-hour light/dark cycle. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5741691/?utm_source=openai))  \n- For sighted people, light signals via the eyes help reset the circadian clock every day. People who are totally blind and have **no light perception** lack that signal entirely, so their internal rhythm often runs longer than 24 hours, drifting gradually out of sync with nighttime and daytime routines. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5741691/?utm_source=openai))\n\n---\n\n### What is Tasimelteon and Why It's Used\n\n- **Tasimelteon** is a *melatonin receptor agonist*\u2014meaning it mimics the effects of melatonin, a hormone your body naturally produces at night to help regulate sleep. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK548636/?utm_source=openai))  \n- It specifically binds to both the **MT\u2081** and **MT\u2082** melatonin receptors. MT\u2082 is especially important for *shifting and entraining* the internal circadian clock, while MT\u2081 helps promote drowsiness or help initiate sleep. ([drugs.com](https://www.drugs.com/monograph/tasimelteon.html?utm_source=openai))\n\n---\n\n### How It Works in Totally Blind People\n\nBecause there\u2019s no light perception to reset the circadian clock:\n\n1. **Tasimelteon** is taken **once every night**, at the *same time* (usually about one hour before the target bedtime). ([drugs.com](https://www.drugs.com/monograph/tasimelteon.html?utm_source=openai))  \n2. Over time (often several weeks), it helps entrain\u2014or synchronize\u2014the internal biological clock to a 24-hour schedule. That means hormone release (like melatonin/cortisol), sleep\u2013wake times, and other physiological rhythms shift to better match the typical day/night cycle. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/?term=26466871&utm_source=openai))  \n3. Key measurements in studies include urinary 6-sulfatoxymelatonin (a stable metabolite of melatonin), sleep durations, daytime sleepiness, etc. In clinical trials, a part of the tasimelteon group achieved entrainment (reset circadian rhythms to 24h) and showed improvement in sleep quality and daytime function compared to placebo. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/?term=26466871&utm_source=openai))\n\n---\n\n### Dosage, Timing, and Pharmacokinetics\n\n- The approved dose is **20 mg orally once daily**, taken without food, at the **same clock time every night** (usually before bed). Missing a dose or taking it at inconsistent times can reduce effectiveness. ([drugs.com](https://www.drugs.com/monograph/tasimelteon.html?utm_source=openai))  \n- It reaches peak levels in the blood generally **0.5 to 3 hours** after dosing (fasted), with a half-life of about **1.3 hours**. That\u2019s relatively short, so timing is important. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5741691/?utm_source=openai))  \n- It is metabolized by liver enzymes (CYP1A2 and CYP3A4), which means there are potential interactions with other medications that affect those enzymes. ([drugs.com](https://www.drugs.com/monograph/tasimelteon.html?utm_source=openai))  \n\n---\n\n### How Effective Is It?\n\n- In the major Phase III SET study, among totally blind people with Non-24 given tasimelteon, about **20%** achieved entrainment after one month, versus ~3% in the placebo group. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5741691/?utm_source=openai))  \n- Those who became entrained saw improvements in nighttime sleep duration and fewer daytime naps during their worst sleep periods. When treatment was continued (in another phase), these benefits were maintained; when tasimelteon was stopped, entrainment was lost and symptoms returned. ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S1389945713016328?utm_source=openai))  \n\n---\n\n### Side Effects, Safety, and Other Considerations\n\n- Common side effects include **headache**, **daytime sleepiness**, **dizziness**, **abnormal or vivid dreams**, and sometimes elevated liver enzymes. Most side effects are mild to moderate. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK548636/?utm_source=openai))  \n- It is well tolerated overall in blind patients with Non-24. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK548636/?utm_source=openai))  \n- Chronic nightly dosing is necessary to maintain entrainment. If therapy is discontinued, the circadian rhythm tends to drift again. ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S1389945713016328?utm_source=openai))\n\n---\n\nIf you like, I can also compare tasimelteon to off-label treatments (like melatonin supplements), or go over what might influence whether someone responds well to treatment."
    },
    {
        "role": "user",
        "content": "can%20people%20become%20dependent%20on%20it"
    },
    {
        "role": "assistant",
        "content": "Here\u2019s what the medical literature and official drug information say about whether people can develop dependence on **tasimelteon (Hetlioz/Hetlioz LQ)**, which is used to treat non-24-hour sleep-wake disorder in totally blind individuals.\n\n---\n\n### Definitions: Dependence vs Addiction\n\n- **Physical dependence** refers to a physiological adaptation where the body becomes used to a drug\u2019s presence. Discontinuing the drug can lead to withdrawal symptoms.\n- **Addiction** or **abuse potential** involves compulsive use despite harm, cravings, and often reward-related effects (e.g., dopamine release in certain brain circuits).\n\n---\n\n### What Studies Show About Tasimelteon\n\n#### Clinical Trials & Monograph Data\n\n- **Phase III trials** (SET and RESET) in totally blind participants with non-24 investigated both the safety and efficacy of tasimelteon over many weeks. Outcomes included measures like entrainment to a 24-hour cycle, sleep-wake timing, and daytime alertness. ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S0140673615600319?utm_source=openai))\n- Safety assessments *did not report signals of abuse or dependence*, in those trials. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/25685859/?utm_source=openai))\n\n#### Labeling, Monographs, and FDA Data\n\n- The drug is **not classified as a controlled substance** under the U.S. Controlled Substances Act, which is a key indicator that regulatory bodies do not consider it to have high abuse potential. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=99cb1928-e57d-4d04-87a1-38108780598a&type=pdf&utm_source=openai))\n\n- From the official *Drug Abuse & Dependence* sections in prescribing information:\n  - Animal behavioral studies: **no signs** of it acting as a reinforcing drug (i.e. animals did *not* self-administer it). ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=99cb1928-e57d-4d04-87a1-38108780598a&type=pdf&utm_source=openai))\n  - Human trials after *chronic administration* (i.e. long-term use) did **not** show physical withdrawal symptoms upon stopping the drug. ([drugs.com](https://www.drugs.com/monograph/tasimelteon.html?utm_source=openai))\n  \n- The monograph specifically states:  \n  > \u201cDiscontinuation \u2026 following chronic administration did not produce withdrawal signs. \u2026 Does not appear to produce physical dependence.\u201d ([drugs.com](https://www.drugs.com/monograph/tasimelteon.html?utm_source=openai))\n\n---\n\n### Summary: Dependence Risk Is Low\n\nBased on the evidence:\n\n- There\u2019s **no evidence** that tasimelteon causes **physical dependence**.\n- There\u2019s **no evidence** of **abuse potential** or addiction in humans or animals as shown in clinical studies and labeling.  \n- There are also **no documented withdrawal effects** when the medication is stopped.\n\n---\n\n### Important Nuances & Considerations\n\n- \u201cDependence\u201d can still refer to an expectation or need to take the drug regularly to maintain therapeutic effects (in this case: keeping sleep-wake cycles entrained). Stopping the medication does typically cause the circadian rhythm to drift again, but that is due to loss of treatment effect\u2014not withdrawal in the classical sense. ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S0140673615600319?utm_source=openai))\n\n- Some people might worry about psychological dependence (e.g., feeling reliant on the medication to sleep). But nothing in the data suggests that there\u2019s a **compulsive behavior component** or **reward-driven misuse** risk.\n\n- As with any medication, individual responses vary\u2014some may not see benefit, may perceive discomfort, or wonder if they are \u201caddicted,\u201d especially if they feel their sleep deteriorates when stopping. These are valid concerns, typically addressed clinically.\n\n---\n\nIf you like, I can pull up what happens when people stop taking tasimelteon (how long until non-24 symptoms return), or compare it to other sleep drugs that *do* have dependence risks."
    },
    {
        "role": "user",
        "content": "where%20can%20I%20get%20tasimelteon"
    },
    {
        "role": "assistant",
        "content": "You *can* get tasimelteon (brand name: Hetlioz or Hetlioz LQ) in the U.S.\u2014but there are several steps involved since it's a prescription medication. Here's how and where to get it, plus tips on managing cost.\n\n---\n\n### \u2705 How to Get Tasimelteon\n\n1. **See a healthcare provider**  \n   Tasimelteon is *prescription-only*. You\u2019ll need a doctor to diagnose Non-24-Hour Sleep-Wake Disorder (Non-24) and write a prescription. ([mayoclinic.org](https://www.mayoclinic.org/drugs-supplements/tasimelteon-oral-route/description/drg-20095155?utm_source=openai))\n\n2. **Use a pharmacy that dispenses specialty medications**  \n   Because it\u2019s a *specialty drug*, many regular retail pharmacies either don\u2019t carry it or only do so on request. Specialty and \u201climited distribution\u201d pharmacies are more likely to be able to fill a prescription for Hetlioz. ([emhp.org](https://emhp.org/portals/19/Documents/For%20EMHP%20Members/Archives/Drug%20Lists%20-%20EMHP/EMHP%20Limited%20Distribution%20Medications%20-%20October%202018.pdf?utm_source=openai))  \n   \n   - **Accredo Specialty Pharmacy** is a known supplier, especially for Veterans Affairs (VA) patients. ([hetliozpro.com](https://www.hetliozpro.com/assets/HETLIOZ-VA-Intake-Form-08427194e50bbb89a008fcbc2e4587eae3475d61c219057d95e740c36f263b89.pdf?utm_source=openai))  \n   - Your doctor\u2019s office or health plan may be able to tell you which local specialty pharmacies carry it.\n\n3. **Check your insurance**  \n   Because the cost is very high, most insurers require prior authorization. Check with your insurance company to understand what paperwork is needed, what your copay would be, and whether they will cover the cost. ([info.caremark.com](https://info.caremark.com/content/dam/enterprise/caremark/microsites/dig/pdfs/pa-cf/cf_rxcriteria/CF_RxCriteria_HETLIOZ_2426-A.pdf?utm_source=openai))\n\n---\n\n### \ud83d\udcb8 Cost & Affordability\n\n- Without insurance, this medication can cost **tens of thousands of dollars per month** (in the range of ~$20,000+) for a standard 30-capsule supply. ([goodrx.com](https://www.goodrx.com/tasimelteon?utm_source=openai))  \n- Some pharmacies and programs *may* offer savings, coupons, or copay cards. For example, Amneal Pharmaceuticals offers a *copay card* that lets some commercially insured patients get monthly supplies for as low as **$0 out-of-pocket** (but terms and eligibility apply). ([amneal.com](https://amneal.com/tasimelteon/?utm_source=openai))  \n- There are also patient assistance or medication access services like **Prescription Hope**, which may provide the drug at a lower fixed price for those who qualify. ([prescriptionhope.com](https://prescriptionhope.com/medication/hetlioz-tasimelteon/?utm_source=openai))\n\n---\n\nIf you tell me which state you\u2019re in (or your insurance status), I can help find *local pharmacies* or programs near you that are likely to carry it affordably."
    }
]